spacer
home > > autumn 2017 > qualified matters
PUBLICATIONS


Qualified Matters

Clinical trials are conducted in research settings, designed to answer specific questions about biomedical or behavioural interventions, including new treatments – such as novel vaccines, drugs, dietary choices and supplements and medical devices – as well as known interventions that warrant further study and comparison. They generate critical data on safety and efficacy, which is then submitted to the regulatory authorities responsible for vetting the risk versus benefit ratio of the trial.

As the demand for new therapies and treatments persists, the need for clinical studies expands globally. This comes with a growing need for organisations to ensure they are able to design, start up and execute their trials, thus delivering critical information regarding the results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marquard Lett is Senior Advisor at UL Compliance to Performance and has over 38 years’ experience in highly regulated industries, including the pharma industry in manufacturing, training and qualification systems, training quality systems and business and manufacturing process improvement.

Gordon Elger
is Senior Advisor at UL Compliance to Performance and has more than 30 years’ experience in the pharma industry in R&D, manufacturing, regulatory affairs, compliance and document management. He has been responsible for regulatory submissions and liaison with agencies at scientific advice meetings, leading the design and implementation of document management systems and is fully conversant with GxP requirements. Email: gordon.elger@ul.com
spacer
Marquard Lett
spacer
spacer
spacer
Gordon Elger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement